Pediatric Growth Hormone Deficiency Clinical Trial
Official title:
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency
Protocol 13VR3 is is a multi-center, open-label study assessing long-term somavaratan
administration.
Patients will be monitored for safety throughout their participation in the study. Safety
will be monitored by physical examination, inspection of injection sites, vital signs,
clinical laboratory determinations (including fasting glucose, insulin, and lipids), 12-lead
ECGs (for new treatment naïve subjects and subjects not previously exposed to somavaratan),
PK/PD assessments, and immunogenicity assessments.
Adverse events (AEs) and concomitant medications will be captured. AEs will be coded using
CTCAE v 4.0. AEs will be coded using the MedDRA dictionary and CMs using the WHO Drug
dictionary.
Protocol 13VR3 is a multi-center, open-label study assessing long-term somavaratan administration. It is open to subjects completing a somavaratan study in children with growth hormone deficiency (GHD), as well as up to 100 new treatment naïve subjects with GHD. All subjects will receive somavaratan 3.5 mg/kg twice monthly. The study will be conducted at approximately 70 Pediatric Endocrinology centers in the United States, Canada, and Europe. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01718041 -
Versartis Trial in Children to Assess Long-Acting Growth Hormone
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05509894 -
Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
|
||
| Completed |
NCT04633057 -
A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Withdrawn |
NCT06113952 -
A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
|
||
| Completed |
NCT01592500 -
Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
|
Phase 2 | |
| Active, not recruiting |
NCT02968004 -
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
|
Phase 3 | |
| Terminated |
NCT02413138 -
Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)
|
Phase 2/Phase 3 |